Compare Apple Inc (AAPL) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Boston Scientific Corporation — how do they compare? Apple Inc trades at $313.85 (market cap $4.56T), while Boston Scientific Corporation trades at $44.49 (market cap $67.33B). The key difference: Apple Inc is far larger — about 67.7× Boston Scientific Corporation's market cap, and Apple Inc pays a 0.35% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| AAPL | BSX | |
|---|---|---|
Market Cap | $4.56T | $67.33B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $108.14 |
52-Week Low | $202.38 | $42.68 |
Enterprise Value | $4.58T | $76.91B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.03, up 0.44% today, with a bullish technical signal from moving averages and a consensus analyst price target of $329.62. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.01 surpassing the $1.95 estimate. Revenue grew to $416.16B in 2025, and net income reached $112.01B. The company maintains strong profitability with a 47.86% gross margin and 27.15% net margin, though valuation ratios like P/E of 37.61 are elevated. A dividend of $0.27 is scheduled for payment on May 14, 2026.
The outlook for AAPL remains positive driven by earnings beats and AI opportunities, but risks include high valuation, competitive pressures, and potential regulatory scrutiny. Institutional sentiment is bullish with 62.73% buy ratings, though technical indicators show mixed signals with RSI suggesting mild overbought conditions near-term.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
